Table 4.
Hazard ratio (95% CI) for progression-free survival and overall survival among epithelial ovarian cancer patients according to the most recent preoperative serum sodium levels measured in the 90 days prior to surgery
| Progression-free survival | Overall survival | |||||
|---|---|---|---|---|---|---|
| Normal | Hyponatremia | P value for Interaction | Normal | Hyponatremia | P value for Interaction | |
| HR (95%CI)† | HR (95%CI)† | HR (95%CI)† | HR (95%CI)† | |||
| All patients | 1.00 (Ref) | 1.58 (1.12-2.23) | 1.00 (Ref) | 1.45 (1.02-2.07) | ||
| FIGO stage | 0.06 | 0.05 | ||||
| I | 1.00 (Ref) | 1.24 (0.25-6.09) | 1.00 (Ref) | 2.30 (0.46-11.38) | ||
| II | 1.00 (Ref) | 1.94 (0.84-4.50) | 1.00 (Ref) | 2.42 (1.00-5.84) | ||
| III | 1.00 (Ref) | 1.19 (0.76-1.86) | 1.00 (Ref) | 0.97 (0.60-1.55) | ||
| IV | 1.00 (Ref) | 3.54 (0.90-13.96) | 1.00 (Ref) | 3.03 (0.87-10.52) | ||
| Residual disease | 0.23 | 0.38 | ||||
| None detectable | 1.00 (Ref) | 1.90 (1.17-3.08) | 1.00 (Ref) | 1.65 (0.97-2.82) | ||
| ≤ 1 cm | 1.00 (Ref) | 0.94 (0.46-1.95) | 1.00 (Ref) | 0.96 (0.46-1.97) | ||
| > 1 cm | 1.00 (Ref) | 2.14 (1.03-4.44) | 1.00 (Ref) | 1.65 (0.81-3.38) | ||
| Comorbidity | 0.07 | 0.32 | ||||
| Yes | 1.00 (Ref) | 1.77 (1.09-2.89) | 1.00 (Ref) | 1.33 (0.80-2.22) | ||
| No | 1.00 (Ref) | 1.43 (0.87-2.34) | 1.00 (Ref) | 1.52 (0.92-2.52) | ||
CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio.
†HRs (95% CIs) for progression-free survival and overall survival were estimated by using multivariable proportional hazard models that were adjusted for age at diagnosis, FIGO, residual disease, performance status, ascites, grading, and preoperative serum potassium level.